Chordate Medical is a Stockholm-based medical technology company that has developed Kinetic Oscillation Stimulation which has proven treatment effects on chronic migraine, as well as allergic and non-allergic rhinitis. The company markets the treatment in Finland, Germany, the United Kingdom, Italy, Israel and Saudi Arabia.
On May 11, Chordate Medical held an annual general meeting where it re-elected Henrik Rammer as Chairman of the Board, and re-elected Tommy Hedberg, Caroline Lundgren brandberg and Gunilla Lundmark as board members. In addition, the meeting elected Otto Skolling as the new vice chairman of the board.
Interview with Otto Skolling, Vice Chairman
In addition to his role as Vice Chairman of Chordate Medical, Otto Skolling is Director Business Development at Nanexa, Chief Business Officer in Asarina Pharma, board member of Respins and Lipidor and CEO and Chairman of the Board of PharmaHe has previously held leading positions in Novozymes, Siemens Life Support Systems and Pharmacia & Upjohn. Basically, he has a master's degree in chemical engineering from Kungliga Tekniska Högskolan in Stockholm.
BioStock contacted Otto Skolling to learn more about his previous experiences, as well as his new role as Vice Chairman of the Board of Chordate Medical.
First of all, how do you see Chordate Medical's potential?
– I am quite new to the company, so it is likely that I do not yet see all the possibilities and potential that the company has. However, it is clear to everyone that being able to offer a treatment for migraine for all those who do not respond to existing medications, and that is a large group, with an effect on par with the best is of course very exciting. Here I believe that Chordate has the opportunity to become a serious alternative for those who do not currently respond to existing medications or who do not want to use these heavy medications that are currently associated with migraine treatment.
Which of your previous experiences are particularly beneficial and useful in the role of Vice Chairman of Chordate Medical?
– I believe that my experience from board assignments in similar smaller life science companies will be important. I have also worked in business development for the last 15 years and hope that I will be able to support Anders and the team in future business processes.
»I believe that my experience from board assignments in similar smaller life science companies will be important. I have also worked in business development for the last 15 years and hope that I will be able to support Anders and the team in future business processes.«
What will be your immediate tasks in the work of realizing Chordate Medical's potential?
– The very first thing will be to get to know the company in depth, spend time with Anders and his team to understand the company's product and indications in depth to create a better picture of the company and its opportunities.
You seem to have a lot of other assignments on your plate. How much of your working time are you expected to spend on the board assignment at Chordate?
– There is no fixed time set for this assignment, but as with most other assignments, it will probably vary over time depending on the needs of the company in addition to the basic time that a board assignment requires.